US 12,447,127 B2
Thermostable vaccine compositions and methods of preparing the same
Kimberly Hassett, Medford, MA (US); Pradyot Nandi, Denver, CO (US); John Carpenter, Littleton, CO (US); and Theodore Randolph, Niwot, CO (US)
Assigned to The Regents of the University of Colorado, a body corporate, Denver, CO (US)
Filed by The Regents of the University of Colorado, a body corporate, Denver, CO (US)
Filed on Apr. 28, 2022, as Appl. No. 17/732,224.
Application 17/732,224 is a continuation of application No. 16/448,647, filed on Jun. 21, 2019, granted, now 11,491,111.
Application 16/448,647 is a continuation of application No. 15/694,023, filed on Sep. 1, 2017, abandoned.
Application 15/694,023 is a continuation of application No. 13/474,661, filed on May 17, 2012, abandoned.
Claims priority of provisional application 61/487,206, filed on May 17, 2011.
Prior Publication US 2023/0007972 A1, Jan. 12, 2023
Int. Cl. A61K 39/395 (2006.01); A61K 9/19 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61K 47/26 (2006.01)
CPC A61K 9/19 (2013.01) [A61K 39/00 (2013.01); A61K 39/39 (2013.01); A61K 47/26 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/55572 (2013.01); Y02A 50/30 (2018.01)] 19 Claims
 
1. A method of preparing an immunologically-active adjuvant-bound immunogenic composition, the method comprising:
(a) providing an aluminum-salt adjuvant; a buffering agent wherein the buffering agent further comprises a volatile salt, the volatile salt is selected from the group consisting of ammonium acetate, ammonium formate, ammonium carbonate, ammonium bicarbonate, triethylammonium acetate, triethylammonium formate, triethylammonium carbonate, trimethylamine acetate trimethylamine formate, trimethylamine carbonate, pyridinal acetate and pyridinal formate; a glass-forming agent wherein the glass-forming agent is selected from the group consisting of trehalose, sucrose, ficoll, dextran, maltotriose, lactose, mannitol and glycine, hydroxyethyl starch, glycine, cyclodextrin and povidone; and at least one protein antigen;
(b) combining (a) together to create a liquid immunogenic formulation; and
(c) freezing the liquid immunogenic formulation in (b) to create a frozen immunogenic formulation.